Betul Oran, MD
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Betul Oran, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:59 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06297629 · A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell TransplantationM.D. Anderson Cancer Center · withdrawn · Allogeneic Stem Cell Transplantation · principal investigator
- Ph2NCT02684162 · Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell TransplantM.D. Anderson Cancer Center · completed · Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome · principal investigator
- Ph2NCT02210065 · Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) ReactivationM.D. Anderson Cancer Center · completed · Leukemia, Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:59 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.